Ophthotech adds former Santen CEO to board

In This List

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

13 Dec, 2018

Author Fatima Aitizaz
Theme Healthcare & Pharmaceuticals

Ophthotech Corp. has elected Adrienne Graves to be a board member, effective Dec. 12.

Graves is the former CEO of Santen Inc., the U.S. arm of Japan-based ophthalmic pharmaceutical company Santen Pharmaceutical Co. Ltd.

In addition, Michael Ross will step down as an independent board member at the end of February 2019.

New York-based Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases.